These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18503992)

  • 21. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
    Sengsayadeth SM; Srivastava S; Jagasia M; Savani BN
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1479-87. PubMed ID: 22449611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD.
    Dietrich-Ntoukas T; Cursiefen C; Westekemper H; Eberwein P; Reinhard T; Bertz H; Nepp J; Lawitschka A; Heiligenhaus A; Seitz B; Messmer EM; Meyer-ter-Vehn T; Basara N; Greinix H; Datiles MB; Lee SJ; Pavletic SZ; Wolff D
    Cornea; 2012 Mar; 31(3):299-310. PubMed ID: 22157574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
    Wolff D; Fatobene G; Rocha V; Kröger N; Flowers ME
    Bone Marrow Transplant; 2021 Sep; 56(9):2079-2087. PubMed ID: 34218265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease.
    Oarbeascoa G; Lozano ML; Guerra LM; Amunarriz C; Saavedra CA; Garcia-Gala JM; Viejo A; Revilla N; Acosta Fleitas C; Arroyo JL; Martinez Revuelta E; Galego A; Hernandez-Maraver D; Kwon M; Diez-Martin JL; Pascual C;
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):651-658. PubMed ID: 31917270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
    Modi B; Hernandez-Henderson M; Yang D; Klein J; Dadwal S; Kopp E; Huelsman K; Mokhtari S; Ali H; Malki MMA; Spielberger R; Salhotra A; Zain J; Cotliar J; Parker P; Forman S; Nakamura R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):265-269. PubMed ID: 30201397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.
    Mielke S; Lutz M; Schmidhuber J; Kapp M; Ditz D; Ammer J; Einsele H; Grigoleit GU; Holler E; Wolff D
    Bone Marrow Transplant; 2014 Nov; 49(11):1412-8. PubMed ID: 25089598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
    Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
    Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
    Saidu NEB; Bonini C; Dickinson A; Grce M; Inngjerdingen M; Koehl U; Toubert A; Zeiser R; Galimberti S
    Front Immunol; 2020; 11():578314. PubMed ID: 33162993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis.
    Goklemez S; Im AP; Cao L; Pirsl F; Steinberg SM; Curtis LM; Mitchell SA; Cowen EW; Baruffaldi J; Rose J; Mays J; Ostojic A; Holtzman NG; Hakim FT; Pavletic SZ
    Am J Hematol; 2020 Apr; 95(4):387-394. PubMed ID: 31903638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
    Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
    Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pericarditis in Patients With Chronic Graft-vs-Host Disease.
    Karakulska-Prystupiuk E; Basak G; Dwilewicz-Trojaczek J; Paluszewska M; Boguradzki P; Jędrzejczak W
    Transplant Proc; 2018 Sep; 50(7):2218-2222. PubMed ID: 30177139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response.
    Seaton ED; Szydlo RM; Kanfer E; Apperley JF; Russell-Jones R
    Blood; 2003 Aug; 102(4):1217-23. PubMed ID: 12714516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
    Teusink-Cross A; Davies SM; Grimley MS; Chandra S; Flannery A; Dandoy CE; Nelson AS; Marsh RA; Jacoby B; Lane A; Khandelwal P
    Pediatr Transplant; 2020 May; 24(3):e13692. PubMed ID: 32202691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease.
    Bisaccia E; Palangio M; Gonzalez J
    Transfus Apher Sci; 2011 Oct; 45(2):187-90. PubMed ID: 21890415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
    Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
    Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.